GeNeuro Beheer

Beheer criteriumcontroles 3/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Jesus Martin-Garcia

Algemeen directeur

€647.9k

Totale compensatie

Percentage CEO-salaris	67.1%
Dienstverband CEO	8.8yrs
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	6yrs
Gemiddelde ambtstermijn bestuur	6.9yrs

Recente managementupdates

Recent updates

Breakeven On The Horizon For GeNeuro SA (EPA:GNRO)

Mar 14

Analysts Expect Breakeven For GeNeuro SA (EPA:GNRO) Before Long

Nov 28

Analyse CEO-vergoeding

Hoe is Jesus Martin-Garcia's beloning veranderd ten opzichte van GeNeuro's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Dec 31 2023	€648k	€435k	-€15m
Sep 30 2023	n/a	n/a	-€14m
Jun 30 2023	n/a	n/a	-€13m
Mar 31 2023	n/a	n/a	-€13m
Dec 31 2022	€805k	€410k	-€12m
Sep 30 2022	n/a	n/a	-€11m
Jun 30 2022	n/a	n/a	-€9m
Mar 31 2022	n/a	n/a	-€8m
Dec 31 2021	€722k	€370k	-€7m
Sep 30 2021	n/a	n/a	-€8m
Jun 30 2021	n/a	n/a	-€8m
Mar 31 2021	n/a	n/a	-€9m
Dec 31 2020	€716k	€374k	-€9m
Sep 30 2020	n/a	n/a	-€9m
Jun 30 2020	n/a	n/a	-€9m
Mar 31 2020	n/a	n/a	-€9m
Dec 31 2019	€735k	€360k	-€9m
Sep 30 2019	n/a	n/a	-€10m
Jun 30 2019	n/a	n/a	-€10m
Mar 31 2019	n/a	n/a	-€9m
Dec 31 2018	€694k	€346k	-€8m
Sep 30 2018	n/a	n/a	-€4m
Jun 30 2018	n/a	n/a	-€192k
Mar 31 2018	n/a	n/a	-€3m
Dec 31 2017	€725k	€360k	-€6m

Compensatie versus markt: De totale vergoeding ($USD 679.19K ) Jesus } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de French markt ($USD 324.83K ).

Compensatie versus inkomsten: De vergoeding van Jesus is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Jesus Martin-Garcia (62 yo)

8.8yrs

Tenure

€647,944

Compensatie

Mr. Jesús Martin-Garcia is the Founding Partner, General Partner, and Director of Eclosion SA. He serves at GeNeuro SA as the Chairman of the Board since February 06, 2006 and Chief Executive Officer since...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Jesus Martin-Garcia	Chairman & CEO	8.8yrs	€647.94k	geen gegevens
Miguel Payró	Group Chief Financial Officer	9yrs	geen gegevens	geen gegevens
Hervé Perron	Chief Scientific Officer	no data	geen gegevens	geen gegevens
Alois Lang	Chief Development Officer	3.2yrs	geen gegevens	geen gegevens
Anke Post	Chief Medical Officer	less than a year	geen gegevens	geen gegevens

6.0yrs

Gemiddelde duur

62yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van GNRO is doorgewinterd en ervaren (gemiddelde ambtstermijn van 6 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Jesus Martin-Garcia	Chairman & CEO	18.8yrs	€647.94k	geen gegevens
Michel Dubois	Independent Director	16.3yrs	€12.90k	geen gegevens
Philippe Archinard	Independent Director	3.5yrs	geen gegevens	geen gegevens
Gordon Francis	Independent Director	9.7yrs	€17.20k	geen gegevens
Giacomo Di Nepi	Independent Director	9.3yrs	€12.90k	geen gegevens
Hedi Brahim	Independent Director	4.5yrs	geen gegevens	geen gegevens
Sandrine Flory	Independent Director	less than a year	geen gegevens	geen gegevens
Pascal Lemaire	Independent Director	less than a year	geen gegevens	geen gegevens

6.9yrs

Gemiddelde duur

63.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van GNRO wordt beschouwd als ervaren (gemiddelde ambtstermijn 6.9 jaar).

GeNeuro Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Geneuro SA Announces Appointments of Board of Directors

Insufficient new directors

GeNeuro SA, Annual General Meeting, Jun 14, 2023

Insufficient new directors

Insufficient new directors

GeNeuro SA, Annual General Meeting, May 31, 2022

Recent updates

New minor risk - Financial data availability

Price target decreased by 49% to €2.05

GeNeuro Announces Results of the Gnc-501 Study in Post-Covid-19 Syndrome

GeNeuro SA Announces Last Patient Last Visit in Its Post-Covid Trial and Confirms Top-Line Results by End of June 2024

Geneuro SA Announces Appointments of Board of Directors

New minor risk - Shareholder dilution

GeNeuro SA has completed a Follow-on Equity Offering in the amount of €4.900246 million.

Geneuro S.A. Recommends Continuing the Trial Evaluating Temelimab in Long Covid Without Modifications

New major risk - Revenue and earnings growth

Forecast to breakeven in 2024

GeNeuro Announces Completion of Recruitment of its Long-COVID Phase 2 Trial and Confirms Top-Line Results for June 2024

GeNeuro Announces Completion of Recruitment of its Long-COVID Phase 2 Trial and Confirms Top-Line Results for June 2024

New major risk - Negative shareholders equity

New minor risk - Share price stability

GeNeuro SA Announces Recent Study Demonstrates the Strong Link Between SARS-CoV-2 Infection and HERV-W Activation in Hospitalized Psychotic Patients

GeNeuro SA to Report First Half, 2023 Results on Sep 29, 2023

New minor risk - Profitability

Insufficient new directors

GeNeuro SA, Annual General Meeting, Jun 14, 2023

Price target decreased to €5.55

Insufficient new directors

GeNeuro SA Announces Recruitment of First Patients in All Five Swiss Centers in the First Personalized Medicine Clinical Trial Against Long-Covid Assessing Temelimab

Geneuro’S Protect-Ms Phase 2 Trial Data, Presented At the Ectrims 2022 Congress in Amsterdam, Confirms Synergistic Neuroprotective Potential of Temelimab in Ms

GeNeuro Will Present Phase IIb Safety and Efficacy Data on Temelimab from its ProTEct-MS Study at the 38thCongress of the European Committee for Treatment and Research in Multiple Sclerosis

Geneuro Is Granted Authorization by the Swiss Health Authority to Initiate A Phase II Study Evaluating Temelimab in Patients with Severe Neuropsychiatric Post-Covid Syndromes

Price target decreased to €5.55

Insufficient new directors

GeNeuro SA, Annual General Meeting, May 31, 2022

GeNeuro and Fondamental Foundation Announce the First Results of the Collaboration for the Development of Diagnostic and Therapeutic Options for Patients with Post-Covid Neuropsychiatric Syndromes

GeNeuro Announces the Completion of Its ProTEct-MS Study and Confirms the March Timeline for Top-line Results

Geneuro Sa unveils Additional Results from the Preclinical Research Program in Amyotrophic Lateral Sclerosis (Als) Developed in Partnership with the National Institute of Neurological Disorders and Stroke

Geneuro Receives EUR 6.4 Million in Funding from the Swiss Government for the Development of Temelimab Against Long-Covid

GeNeuro Announces First Patient Having Finished the ProTEct-MS Study at the Karolinska Institutet’s Academic Specialist Center Has Entered the Study Extension

GeNeuro Announces the Publication in Multiple Sclerosis of Results From CHANGE-MS and ANGEL-MS Studies

Geneuro Presents Data Supporting Pathogenic Role of an Endogenous Retroviral Protein (HERV-W ENV) in Post-Covid Neuropsychiatric Syndrome

Consensus forecasts updated

Breakeven On The Horizon For GeNeuro SA (EPA:GNRO)

GeNeuro SA Announces Independent Drug Safety Monitoring Board (Dsmb) Has Concluded the Phase 2 Trial of Temelimab in Ms Patients

GeNeuro Completes Patient Recruitment in Temelimab Phase 2 Multiple Sclerosis Trial at the Karolinska Institutet’s Academic Specialist Center (ASC)

New 90-day high: €3.92

New 90-day low: €2.60

Analysts Expect Breakeven For GeNeuro SA (EPA:GNRO) Before Long

New 90-day low: €2.62

New 90-day low: €3.00

New 90-day low: €3.01

GeNeuro SA Announces Management Changes

GeNeuro SA to Report First Half, 2020 Results on Sep 29, 2020

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd